For more information, visit Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Apollo's products are offered in over 75 countries today and include the OverStitch® Endoscopic Suturing System, the OverStitch Sx TM Endoscopic Suturing System, the Orbera® Intragastric Balloon System, the X-Tack® Endoscopic HeliX Tacking System, as well as the Apollo ESG TM, Apollo ESG Sx TM, Apollo REVISE TM and Apollo REVISE Sx TM Systems. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. is a medical technology company focused on development of next-generation, minimally invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions, including closure of gastrointestinal defects, managing gastrointestinal complications, and weight loss as a treatment of obesity. is serving as financial advisor and Cooley LLP is serving as legal advisor to Apollo.Īpollo Endosurgery, Inc. Upon the completion of the transaction, Apollo will become a wholly-owned subsidiary of Boston Scientific. Certain stockholders representing 8.4% of Apollo's outstanding shares of common stock have agreed to vote their shares in favor of the transaction. The transaction is subject to the satisfaction of customary closing conditions, including approval by a majority of Apollo's stockholders and applicable regulatory approval, and is expected to close in the first half of 2023. The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price of Apollo's common stock on Novemand the volume weighted average closing price of Apollo's common stock in the three months prior to announcement of the transaction. This transaction has been unanimously approved by the Apollo Board of Directors. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.
🚨Disclaimer: Will performing these movements help you surf Pipe? NO! There is very little carryover from performing land-based “surf-specific” exercises to the water, so don’t get it twisted! We just like to have a little fun in our classes and performing these movements in a fatigued state helps improve proprioception and challenge the CNS 🧠.Boston Scientific to acquire Apollo for $10.00 per share in cashĪUSTIN, TX / ACCESSWIRE / Novem/ Apollo Endosurgery, Inc.
#indoboardhero Had some requests for a couple of Indo Board exercises so these are some of our favorites! Remember to tag + #indoboard and you might get featured! Let’s start this Friday and weekend off right INDO BOARD Fam! Swipe right, and try out these exercises! AND train with Team Rider Paul Norris and you too can be as strong as a world champion or Olympic medalist!
0 kommentar(er)
